Two releases, on 19 August. Nightingale Health spent its operating chief's role on commercial leadership ten weeks after cutting its growth target — while the finance seat stays with the founder.
Nightingale Health published two leadership releases on 19 August. Janna Ranta, chief operating officer since May 2025, became Chief Commercial Officer, Research and Healthcare. Hugh Watson, who has spent 25 years in United States laboratory diagnostics, joined from outside as Chief Commercial Officer, Americas. Both changes took effect that day. Both changes took effect that day, and the operating role Ranta leaves behind will not be filled.
Taken separately, the two releases are a busy morning in Helsinki. Taken together, they are one decision: Nightingale Health has turned an operating seat into a selling seat, at the point where it needs the Americas to start producing revenue.
The appointments move two leadership roles fully onto the commercial side
Following the appointments, two new seats now hold fully commercial roles. Suna tied the timing to a completed build phase. "In the past year, we invested heavily in refreshing our core product, the Nightingale Health Check. That work required strong operational management, and Janna had a crucial role in completing the successful product refresh. With strong data on product-market fit, I'm excited to allocate more investment to our commercial scaling, and I warmly welcome Janna to her new role."
The growth downgrade came first
Nightingale Health entered its 2025 to 2026 financial year targeting revenue growth above 50%, and restated that target in March alongside half-year revenue of EUR 2.41 million and an operating loss of EUR 8.80 million for July to December 2025.
On 8 June it reduced the target to approximately 20%, plus or minus 5%, after roughly EUR 2 million of revenue from one project moved into the following financial year for reasons the company said were outside its control.
Suna's framing at the time was that "the reason is timing, not lost business," with revenue in the next financial year expected to exceed EUR 10 million.
Ten weeks later that framing has resource attached to it.
Watson runs execution in the Americas, Ranta keeps group-level oversight of it
The structure is worth noting. Ranta takes global research leadership and group-level oversight of the healthcare business in the Americas. Watson owns commercial execution in the region day to day, working alongside her rather than beneath her.
Watson's record sits squarely in the market the company is trying to open: two decades at Genova Diagnostics, rising from sales into vice-president roles, followed by a period as senior vice president at Boston Heart Diagnostics, a cardiometabolic laboratory in the United States. His own account of the move was about pace. "Throughout my career, I have built commercial organizations in laboratory diagnostics, and I am particularly drawn to companies where commercial execution must keep pace with scientific innovation. Nightingale Health is exactly that: technology validated at a scale our industry rarely sees, and a commercial opportunity in the Americas to match. I look forward to building it "
Suna was explicit about what the hire signals: "Attracting a commercial leader of Hugh's caliber says a lot about where Nightingale Health is heading."
A split like this buys two things at once, regional credibility from an outside hire and continuity from the insider who ran the product refresh. That reading of the split is interpretation.
Suna has been his own interim CFO for eight months
Nightingale Health's commercial organisation gained two chiefs in one morning. Its finance seat has been open since 8 December 2025, when Tuukka Paavola left after four years in the role and Suna stepped in on an interim basis while a search began.
Four days later the company disclosed a wider management change: chief scientific officer Jeffrey Barrett would leave by March 2026, a chief medical officer would be recruited in his place rather than a new scientific officer, and the finance search would continue in order to support international sales growth.
Eight months on, based on the disclosures reviewed for this piece, no permanent appointment to that role has been announced. The founder is still carrying it, through a downgrade and now through a commercial build-out.
·
5 min read
Explore and follow profiles from this article to get timely updates:
Two releases, on 19 August. Nightingale Health spent its operating chief's role on commercial leadership ten weeks after cutting its growth target — while the finance seat stays with the founder.
Nightingale Health published two leadership releases on 19 August. Janna Ranta, chief operating officer since May 2025, became Chief Commercial Officer, Research and Healthcare. Hugh Watson, who has spent 25 years in United States laboratory diagnostics, joined from outside as Chief Commercial Officer, Americas. Both changes took effect that day. Both changes took effect that day, and the operating role Ranta leaves behind will not be filled.
Taken separately, the two releases are a busy morning in Helsinki. Taken together, they are one decision: Nightingale Health has turned an operating seat into a selling seat, at the point where it needs the Americas to start producing revenue.
The appointments move two leadership roles fully onto the commercial side
Following the appointments, two new seats now hold fully commercial roles. Suna tied the timing to a completed build phase. "In the past year, we invested heavily in refreshing our core product, the Nightingale Health Check. That work required strong operational management, and Janna had a crucial role in completing the successful product refresh. With strong data on product-market fit, I'm excited to allocate more investment to our commercial scaling, and I warmly welcome Janna to her new role."
The growth downgrade came first
Nightingale Health entered its 2025 to 2026 financial year targeting revenue growth above 50%, and restated that target in March alongside half-year revenue of EUR 2.41 million and an operating loss of EUR 8.80 million for July to December 2025.
On 8 June it reduced the target to approximately 20%, plus or minus 5%, after roughly EUR 2 million of revenue from one project moved into the following financial year for reasons the company said were outside its control.
Suna's framing at the time was that "the reason is timing, not lost business," with revenue in the next financial year expected to exceed EUR 10 million.
Ten weeks later that framing has resource attached to it.
Watson runs execution in the Americas, Ranta keeps group-level oversight of it
The structure is worth noting. Ranta takes global research leadership and group-level oversight of the healthcare business in the Americas. Watson owns commercial execution in the region day to day, working alongside her rather than beneath her.
Watson's record sits squarely in the market the company is trying to open: two decades at Genova Diagnostics, rising from sales into vice-president roles, followed by a period as senior vice president at Boston Heart Diagnostics, a cardiometabolic laboratory in the United States. His own account of the move was about pace. "Throughout my career, I have built commercial organizations in laboratory diagnostics, and I am particularly drawn to companies where commercial execution must keep pace with scientific innovation. Nightingale Health is exactly that: technology validated at a scale our industry rarely sees, and a commercial opportunity in the Americas to match. I look forward to building it "
Suna was explicit about what the hire signals: "Attracting a commercial leader of Hugh's caliber says a lot about where Nightingale Health is heading."
A split like this buys two things at once, regional credibility from an outside hire and continuity from the insider who ran the product refresh. That reading of the split is interpretation.
Suna has been his own interim CFO for eight months
Nightingale Health's commercial organisation gained two chiefs in one morning. Its finance seat has been open since 8 December 2025, when Tuukka Paavola left after four years in the role and Suna stepped in on an interim basis while a search began.
Four days later the company disclosed a wider management change: chief scientific officer Jeffrey Barrett would leave by March 2026, a chief medical officer would be recruited in his place rather than a new scientific officer, and the finance search would continue in order to support international sales growth.
Eight months on, based on the disclosures reviewed for this piece, no permanent appointment to that role has been announced. The founder is still carrying it, through a downgrade and now through a commercial build-out.
Follow moves like this on the Listeds Executive Intelligence Platform.
Investor Event
Listeds Investor Event · Defence
Nordic defence is in a once-in-a-generation growth cycle. Eight listed and pre-IPO companies pitch to 100+ invited investors at Valkoinen Sali, Helsinki
21 September 2026
Latest on Listeds
